Updated on 31 December 2012
Good news for venous thromboembolism patients - Bristol-Myers Squibb (BMS)-Pfizer anticoagulant drug Eliquis (apixaban) gets FDA nod
Singapore: US FDA has approved Bristol-Myers Squibb (BMS) and Pfizer's anticoagulant drug Eliquis (apixaban). The drug had previously been approved by the European Commission and the Japanese Ministry of Health, Labor and Welfare (MHLW).
Eliquis is used for the prevention of venous thromboembolism and venous thromboembolic event. FDA approved the use of apixaban in December 2012 with an indication of reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
